AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00923559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual at Child Health Centre
Description: Treatment as usual (TAU) involved scheduled nurse calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The nurse is encouraged to promote attachment and to detect postnatal depressions. Mothers might be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment might be initiated by the nurse or the mother. This was registered at the end-point interview.
Study NCT00923559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother-Infant Psychoanalytic treatment (MIP)
Description: MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. In the study, the analysts strived to recruit the baby for an emotional interchange, though this did not imply any belief that the infant would understand verbal communication. Rather, the analyst addressed the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst took care in enrolling the participant mother. This was to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her space to vent her own frustration, depression and anxiety.
Study NCT03189615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Single oral dose of 10 mg Lu AF35700
Study NCT00811577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
Study NCT00811577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
Study NCT00811577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZX100
Description: AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
Study NCT00847288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Review Arm
Description: Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
Study NCT00847288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quarterly Review Arm
Description: Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
Study NCT02360384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linaclotide
Description: Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.
Study NCT02360384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linaclotide
Description: Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.
Study NCT02360384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FODMAP diet
Description: Patients with irritable bowel syndrome with alternating bowel habit will be commenced on the either the low FODMAP diet or a control healthy eating diet.
Study NCT02641769 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: intervention with transplantation of autologous purified stem cells
Study NCT02436421 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Practice Alert based in the Electronic Medical Record
Study NCT01150123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus (GBS) vaccine- low dose
Study NCT01150123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus (GBS) vaccine- High dose
Study NCT01150123 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Saline
Study NCT02953379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMS Mometasone gel
Description: The patient should administer 2 spray in each nostril, once daily.
Study NCT02953379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone spray nasal
Description: The patient should administer 2 spray in each nostril, once daily.
Study NCT04094467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 0.25 mg subcutaneous injection daily for 6 days
Study NCT04094467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: 0.25 mg subcutaneous injection daily for 6 days
Study NCT04094467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: 0.1 mg subcutaneous injection daily for 12 days
Study NCT02883894 — intervention group
Intervention type: OTHER
Intervention: Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9
Study NCT03942991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: articaine
Description: infiltration injection of 4%artpharmadent
Study NCT03942991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine 2% Injection
Description: infiltration injection of 2% Mepecaine-L
Study NCT01475513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Cyclen®
Description: Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
Study NCT00158301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT sessions will focus on teaching participants skills to manage depressed moods and to identify situations which might put them at risk for a relapse in depressive symptoms.
Study NCT01797289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer
Study NCT04130230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: Neostigmine continuous infusion plus standard therapy for sepsis and septic shock.
Study NCT04130230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy for sepsis and septic shock
Study NCT02515045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TriMoxiVanc
Description: triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
Study NCT02515045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin HCl 0.5%
Description: Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
Study NCT02515045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilevro
Description: NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
Study NCT01331850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000 mg or 1200 mg daily oral doses for 48 weeks
Study NCT01331850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 microgram subcutaneously once weekly for 24 weeks
Study NCT01331850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 180 microgram subcutaneously once weekly for 48 weeks
Study NCT01331850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000 mg oral doses twice a day for 24 weeks
Study NCT02515045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate 1%
Description: Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
Study NCT01331850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg oral doses twice a day for 24 weeks
Study NCT01331850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg oral doses twice a day for 24 weeks
Study NCT04190758 — intervention group
Intervention type: OTHER
Intervention: Care as usual
Description: No intervention will be given. The study will follow the effects of care as usual.
Study NCT04366323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
Description: Two doses of 80 million adipose-tissue derived mesenchymal stem cells
Study NCT00402116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles~Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles
Study NCT00402116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 75 milligrams per meter squared (mg/m\^2), oral, daily, 6 weeks then 200 mg/m\^2, oral, daily, twelve 28 day cycles
Study NCT00402116 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks
Study NCT00577603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesh reinforcement of stoma
Description: Patients randomized to receive mesh will undergo stoma formation and will have a 8 cm x 12 cm piece of AlloDerm graft placed as a tissue reinforcement around the stoma and extending under the midline incision. The mesh will be trimmed to provide a minimum of 3cm of overlap around the stoma in all directions. The mesh will be secured with transabdominal number one Prolene (Ethicon, Inc) sutures every 4cm around the mesh. Additional fixation will be provided with Protack spiral tacks (US Surgical, Inc) every 1cm around the mesh. The midline fascia will be closed with running number one Prolene sutures. Skin will be closed in standard fashion.
Study NCT00577603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention
Study NCT00158301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug therapy
Description: All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
Study NCT00158301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug therapy
Description: All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
Study NCT00001151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1,25-Dihydroxycholecalciferol
Description: Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day. All patients in this study received very high doses or 5-20 ug per day.
Study NCT01047215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole; Quetiapine
Description: Aripiprazole Quetiapine
Study NCT00983151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride & Placebo
Description: 89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
Study NCT00983151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol Hydrochloride & Placebo
Description: 89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
Study NCT01429272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 100 mg po bid for 6 weeks
Study NCT01429272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81 mg po bid for 6 weeks
Study NCT01429272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for minocycline and/or aspirin
Study NCT04116138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salovum
Description: Egg yolk powder enriched for anti secretory factor
Study NCT01062555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine & Cellcept
Description: Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
Study NCT01062555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf & Cellcept
Description: Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
Study NCT01062555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose CNI (Cyclosporine or FK) and Cellcept
Description: Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
Study NCT01062555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamune and Cellcept
Description: Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
Study NCT03035955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic acid
Description: 15% gel twice daily for four weeks to one side of face
Study NCT01470742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
Study NCT01470742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELODA
Description: Capecitabine 1000mg/m2 bid D1-14 every 3weeks
Study NCT02488603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aids (tamoxifen-related educational materials in brochure or mobile app)
Description: Decision aids (tamoxifen-related educational materials in brochure or mobile app)
Study NCT02488603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Study NCT03836196 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LDR Brachytherapy and External Beam Radiation Therapy
Description: Low Dose Rate Brachytherapy (LDR-PB) and External Beam Radiation Therapy (EBRT)
Study NCT00978068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir (LPV/r)
Study NCT00978068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine (NVP)
Description: NVP will be used for children \< 3 years of age
Study NCT00978068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz (EFV)
Description: EFV for children ≥3 years of age
Study NCT00978068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 nucleoside reverse transcriptase inhibitor (NRTI)
Description: The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin \< 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
Study NCT03486093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training and retraining to GAVECELT bundle recommendations plus port protector
Description: Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed.~After the first training meeting, the use of Curos® Disinfecting Port Protector for needleless valves port-protector has been introduced.
Study NCT03486093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training and retraining to GAVECELT bundle recommendations
Description: Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed.
Study NCT03010111 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: QFT-IT Test and other blood sampling
Description: In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.
Study NCT03526458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium:YAG laser
Description: Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)
Study NCT03526458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser
Description: Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)
Study NCT04910009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Four sessions of practical privacy education
Description: Two sessions of theoretical, four sessions of practical privacy education
Study NCT01867463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-EPA/Alhydrogel
Description: The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
Study NCT00586183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
Study NCT03187457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metronidazole
Description: Women with Bacterial Vaginosis treated with Metronidazole for 5 days
Study NCT03187457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control: no treatment
Description: Healthy women without Bacterial Vaginosis
Study NCT03293732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCB07010
Description: A protein based adjuvant originated from prokaryotic organism.
Study NCT03293732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HA antigens
Description: HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).
Study NCT03293732 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HA antigens
Description: HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).
Study NCT02912234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Multiple-dose clarithromycin and single-dose Apixaban
Study NCT02912234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Multiple-dose clarithromycin and single-dose Apixaban
Study NCT00827255 — intervention group
Intervention type: DRUG
Intervention: Cyclosporine Ophthalmic Emulsion 0.05%
Description: One drop two times a day approximately 12 hours apart